The Jenex Corporation Reports Promising Initial Results on Zika Virus Testing with TherOZap(TM)

1024 379 Techna

Toronto, Ontario–(Newsfile Corp. – October 12, 2017) – The Jenex Corporation (TSXV: JEN.H) (“Jenex” or the “Company”), a progressive medical device technology company, today announces that it has received promising initial results on the Zika virus testing with TherOZap.

Dr. Alyson Kelvin at UHN reported the following:
“To evaluate the effectiveness of the Jenex TherOZap device against the infectivity of Zika virus, cells were infected with a range of Zika virus doses and treated with the Jenex device with heat. In the cells that received the lowest viral dose, initial results showed infected cells that had been treated with the Jenex TherOZap device had a markedly lower cytopathic effect compared to infected cells that did not receive treatment. These preliminary results need to be confirmed through repeated testing as well as by measurement of virus viability. Cytopathic effect is a measure of cellular pathogenesis and cellular viability in relation to viral infection; results of a viral replication assay and measurements of live viral activity are pending.”

Mr. Rob Fia, CEO, commented:
“We are pleased with the initial test results on the Zika Virus with our patent pending TherOZap™ technology. Jenex is excited about these initial tests results and we look forward to further data as it becomes available from Techna Institute at UHN. Jenex will have more to report to over the next several weeks.”

View the Full Press Release